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Introduction: Cell-based therapies (CBTs) have been shown to confer regenerative 
capacity in various pathologies. The production of such treatments requires 
a range of business models. These business models either align with or disrupt 
the current clinical pathway and therefore it is imperative to understand the 
impact at the clinical interface and to design manufacture and supply networks 
in a way that makes adoption as simple as possible. 
The present study explores the delivery of cell therapy within several NHS 
Trust hospitals. CBTs are manufactured under a controlled GMP background, 
requiring specialist equipment and expertise. This often presents unexpected costs 
and operational procedures that are unfamiliar to the typical clinical environment. 
 
Methods: This project takes a focus on the flow of information and activities 
from ‘needle-to-needle’ for a culture-expanded autologous chondrocyte implantation 
(ACI) product in a Phase-II clinical trial at a local NHS Trust. A 
framework has been identified based on conceptual modelling under the IDEF0 
standard to understand fundamental unit operations. Activity-based costing has 
been applied to value-adding activities to assess direct and indirect costs of manufacture. 
A sensitivity analysis has explored how manufacturing parameters, facility 
overheads and the operational model has impacted upon the cost drivers. 
Comparison of CBT manufacture at further NHS sites has been explored 
to understand current practices and the feasibility of change to allow for increased 
capacity within the constraints of existing infrastructure. Semi-structured 
interviews have been undertaken with key players through the 
innovation, adoption and implementation process. Consensus statements have 
been developed through a two-round Delphi method in order to provide guidance 
for prospective CBT manufacturers and the NHS. 
 
Results: This mixed methods approach explores and validates perspectives on 
CBTs within the hospital environment. Clinicans, pharmacists, production and 
quality scientists have been surveyed from several NHS hospitals across England. 
It is clear from these discussions that several characteristics of the supply chain 
are unique to CBTs, including their effect on logistics, distribution, reimbursement 
and the supply route to the point-of-care. 
 
Conclusion: This study will support a body of research to understand and develop 
a framework for the clinically integrated manufacture of CBTs and other such 
advanced therapies within the NHS. 
